SMT201600019B - Forma di base libera cristallina di un composto bifenilico - Google Patents

Forma di base libera cristallina di un composto bifenilico

Info

Publication number
SMT201600019B
SMT201600019B SM201600019T SM201600019T SMT201600019B SM T201600019 B SMT201600019 B SM T201600019B SM 201600019 T SM201600019 T SM 201600019T SM 201600019 T SM201600019 T SM 201600019T SM T201600019 B SMT201600019 B SM T201600019B
Authority
SM
San Marino
Prior art keywords
basic form
crystalline free
biphenyl compound
free basic
biphenyl
Prior art date
Application number
SM201600019T
Other languages
English (en)
Inventor
Grahame Woollam
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42562758&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201600019(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of SMT201600019B publication Critical patent/SMT201600019B/it

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • A61K9/124Aerosols; Foams characterised by the propellant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/64Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having an aryl radical as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SM201600019T 2009-07-15 2016-01-20 Forma di base libera cristallina di un composto bifenilico SMT201600019B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22580309P 2009-07-15 2009-07-15
PCT/US2010/041903 WO2011008809A1 (en) 2009-07-15 2010-07-14 Crystalline freebase forms of a biphenyl compound

Publications (1)

Publication Number Publication Date
SMT201600019B true SMT201600019B (it) 2016-02-25

Family

ID=42562758

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201600019T SMT201600019B (it) 2009-07-15 2016-01-20 Forma di base libera cristallina di un composto bifenilico

Country Status (21)

Country Link
US (11) US8541451B2 (it)
EP (2) EP2453894B1 (it)
JP (4) JP5651174B2 (it)
KR (1) KR101742252B1 (it)
CN (1) CN102470130B (it)
AU (1) AU2010273514B2 (it)
BR (1) BR112012000890A2 (it)
CA (2) CA2765621C (it)
DK (1) DK2453894T3 (it)
ES (2) ES2639642T3 (it)
HK (2) HK1168050A1 (it)
HR (1) HRP20151344T1 (it)
HU (1) HUE026414T2 (it)
IL (1) IL216995A (it)
MX (1) MX2012000682A (it)
PL (2) PL2987490T3 (it)
PT (1) PT2453894E (it)
SG (2) SG10201407913UA (it)
SI (1) SI2453894T1 (it)
SM (1) SMT201600019B (it)
WO (1) WO2011008809A1 (it)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
JP5651174B2 (ja) 2009-07-15 2015-01-07 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー ビフェニル化合物の結晶性遊離塩基形
JP5959117B2 (ja) 2010-07-13 2016-08-02 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー ビフェニル−2−イルカルバミン酸を調製するためのプロセス
CN105008357A (zh) * 2013-02-21 2015-10-28 辉瑞大药厂 选择性cdk4/6抑制剂的固态形式
WO2015070366A1 (en) 2013-11-12 2015-05-21 Merck Sharp & Dohme Corp. Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug
CN112694434B (zh) * 2020-12-29 2023-06-16 浙江和泽医药科技股份有限公司 一种雷芬那辛新中间体及其活性亲电砌块和雷芬那辛的新制备方法
WO2023104920A1 (en) 2021-12-09 2023-06-15 Medichem, S.A. Crystalline acetone solvate of revefenacin
CN114276290B (zh) * 2021-12-24 2024-05-28 浙江和泽医药科技股份有限公司 一种雷芬那辛无水晶型及其制备方法
CN117180235A (zh) * 2023-09-19 2023-12-08 山东京卫制药有限公司 一种无定型雷芬那辛吸入制剂
CN117263848A (zh) * 2023-09-19 2023-12-22 山东京卫制药有限公司 一种雷芬那辛的吸入喷雾剂
CN117263849A (zh) * 2023-09-19 2023-12-22 山东京卫制药有限公司 一种雷芬那辛三水合物晶型及其制备方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2425983C3 (de) * 1973-06-12 1978-09-14 Toyama Chemical Co. Ltd., Tokio Sulfonsäuresalze von Acylcholinen, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzung
BR8007911A (pt) 1979-12-06 1981-06-16 Glaxo Group Ltd Inalador aperfeicoado
CY1492A (en) 1981-07-08 1990-02-16 Draco Ab Powder inhalator
FR2585563B1 (fr) 1985-07-30 1993-11-12 Glaxo Group Ltd Dispositif pour administrer des medicaments a des patients
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
SK280967B6 (sk) 1990-03-02 2000-10-09 Glaxo Group Limited Inhalačný prístroj
US6006745A (en) 1990-12-21 1999-12-28 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
AU2178392A (en) 1991-06-12 1993-01-12 Minnesota Mining And Manufacturing Company Albuterol sulfate suspension aerosol formulations
US5337740A (en) 1991-08-01 1994-08-16 New England Pharmaceuticals, Inc. Inhalation devices
ATE150296T1 (de) 1991-12-18 1997-04-15 Minnesota Mining & Mfg Aerosolzusammensetzungen für arzneimittelsuspensionen
US5239993A (en) 1992-08-26 1993-08-31 Glaxo Inc. Dosage inhalator providing optimized compound inhalation trajectory
US5415162A (en) 1994-01-18 1995-05-16 Glaxo Inc. Multi-dose dry powder inhalation device
WO1995021820A1 (fr) 1994-02-10 1995-08-17 Yamanouchi Pharmaceutical Co., Ltd. Nouveau derive du carbamate et composition correspondante
US5983956A (en) 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
US5637820A (en) * 1995-01-06 1997-06-10 Wittman; Kenneth L. Stringed instrument with on-board tuner
SE9501384D0 (sv) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
NZ306280A (en) 1995-04-14 1999-07-29 Glaxo Wellcome Inc Metered dose inhaler for salmeterol
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
AU9281298A (en) 1997-10-01 1999-04-23 Kyowa Hakko Kogyo Co. Ltd. Benzodioxole derivatives
JP2002506856A (ja) 1998-03-14 2002-03-05 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング フタラジノンpdeiii/iv阻害剤
PL343491A1 (en) 1998-04-18 2001-08-27 Glaxo Group Ltd Pharmaceutical aerosol formulation
GB9808802D0 (en) 1998-04-24 1998-06-24 Glaxo Group Ltd Pharmaceutical formulations
SE9804000D0 (sv) 1998-11-23 1998-11-23 Astra Ab New composition of matter
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
JP2002541183A (ja) 1999-04-14 2002-12-03 グラクソ グループ リミテッド 医薬用エアゾール製剤
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
WO2002070490A1 (en) 2001-03-08 2002-09-12 Glaxo Group Limited Agonists of beta-adrenoceptors
WO2002076933A1 (en) 2001-03-22 2002-10-03 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
US20030018019A1 (en) * 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
ES2438985T3 (es) 2001-09-14 2014-01-21 Glaxo Group Limited Formulación de inhalación que comprende derivados de fenetanolamina para el tratamiento de enfermedades respiratorias
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
PE20050973A1 (es) * 2003-10-29 2005-11-19 Theravance Inc Sales de acido naftalen-1,5-disulfonico de un compuesto de 4-amino-1-(piridilmetil)piperidina como antagonistas de receptores muscarinicos
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
TW200540154A (en) * 2004-06-10 2005-12-16 Theravance Inc Crystalline form of a substituted pyrrolidine compound
US20060205949A1 (en) * 2005-03-10 2006-09-14 Theravance, Inc. Crystalline forms of a biphenyl compound
TWI372749B (en) * 2005-03-10 2012-09-21 Theravance Inc Crystalline forms of a biphenyl compound
US7465870B1 (en) * 2008-03-11 2008-12-16 Homan Randy W Illuminated heart-shaped guitar with strobe lights and a modified bridge
JP5651174B2 (ja) 2009-07-15 2015-01-07 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー ビフェニル化合物の結晶性遊離塩基形
JP5959117B2 (ja) 2010-07-13 2016-08-02 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー ビフェニル−2−イルカルバミン酸を調製するためのプロセス

Also Published As

Publication number Publication date
US9765028B2 (en) 2017-09-19
KR20130027004A (ko) 2013-03-14
US20130338191A1 (en) 2013-12-19
US11691948B2 (en) 2023-07-04
US20200308116A1 (en) 2020-10-01
IL216995A (en) 2017-10-31
US20190248743A1 (en) 2019-08-15
EP2453894B1 (en) 2015-11-04
EP2453894A1 (en) 2012-05-23
HK1168050A1 (zh) 2012-12-21
US20150164796A1 (en) 2015-06-18
JP2012533550A (ja) 2012-12-27
WO2011008809A1 (en) 2011-01-20
US9415041B2 (en) 2016-08-16
CA2989129C (en) 2021-03-09
PL2987490T3 (pl) 2017-12-29
SG178036A1 (en) 2012-03-29
SG10201407913UA (en) 2015-01-29
PT2453894E (pt) 2016-02-02
HRP20151344T1 (hr) 2016-01-01
US10550081B2 (en) 2020-02-04
CA2989129A1 (en) 2011-01-20
MX2012000682A (es) 2012-02-28
DK2453894T3 (en) 2016-01-25
US11649209B2 (en) 2023-05-16
US9226896B2 (en) 2016-01-05
US8921396B2 (en) 2014-12-30
US11858898B2 (en) 2024-01-02
EP2987490B1 (en) 2017-06-14
SI2453894T1 (sl) 2016-02-29
HK1219415A1 (zh) 2017-04-07
IL216995A0 (en) 2012-02-29
AU2010273514B2 (en) 2015-01-22
CA2765621A1 (en) 2011-01-20
CN102470130B (zh) 2013-09-04
US20180186740A1 (en) 2018-07-05
US20220009890A1 (en) 2022-01-13
US20170081283A1 (en) 2017-03-23
BR112012000890A2 (pt) 2017-10-31
US20220306580A1 (en) 2022-09-29
US20230303492A1 (en) 2023-09-28
ES2557553T3 (es) 2016-01-27
US10100013B2 (en) 2018-10-16
JP5651174B2 (ja) 2015-01-07
KR101742252B1 (ko) 2017-05-31
JP6338505B2 (ja) 2018-06-06
PL2453894T3 (pl) 2016-04-29
CA2765621C (en) 2018-02-13
EP2987490A1 (en) 2016-02-24
US20160143897A1 (en) 2016-05-26
HUE026414T2 (hu) 2016-05-30
US11008289B2 (en) 2021-05-18
ES2639642T3 (es) 2017-10-27
JP2017171692A (ja) 2017-09-28
JP2016026214A (ja) 2016-02-12
JP2015003929A (ja) 2015-01-08
US20110015163A1 (en) 2011-01-20
US8541451B2 (en) 2013-09-24
AU2010273514A1 (en) 2012-01-19
CN102470130A (zh) 2012-05-23

Similar Documents

Publication Publication Date Title
SMT201600019B (it) Forma di base libera cristallina di un composto bifenilico
HRP20192133T8 (hr) Kemijski spoj koristan kao posrednik za pripremu inhibitora katekol-o-metiltransferaze
CY2017026I1 (el) Τετρακυκλικη ενωση
SMT201600008B (it) Composti di piridazinone
ZA201301802B (en) Besylate salt of a btk inhibitor
IT1396026B1 (it) Composizioni fotoluminescenti per convertitori di spettro a migliorata efficienza
BRPI1013868A2 (pt) composto diaciletilenodiamina
PT2611779T (pt) Formas cristalinas de um inibidor do fator xa
DK3792254T3 (da) Krystallinske methylthioninium-chloridhydrater
EP2483366A4 (en) DEUTERATED COMPOUNDS FOR LUMINESCENT APPLICATIONS
EP2427531A4 (en) DEUTERIZED CONNECTIONS FOR LUMINESCENCE APPLICATIONS
IL213725A0 (en) Novel forms of bendamustine free base
SMT201700085B (it) Forma cristallina di pemirolast
IT1401097B1 (it) Caricatore di utensili
EP2516380A4 (en) DETERIORATED COMPOUNDS FOR LUMINESCENT APPLICATIONS
FR2946241B1 (fr) Zesteur a savon
ZA201104319B (en) Crystalline forms of a 3-carboxypropyl-aminotetralin compound
BRPI1013729A2 (pt) compostos bisazo
ZA201300154B (en) Crystalline form of a 3-phenoxymethylpyrrolidine compound
BRPI1014266A2 (pt) Compostos bisazo
FI20095226A (fi) Menetelmä piiyhdisteen muodostamiseksi
TH0901005813A (th) สารประกอบ
TH119679B (th) สารประกอบบิสเบนโซซาซิโนน
TH106773B (th) 4-ไตรเมธิลแอมโมนิโอ-บิวไทเรทในฐานะสารยับยั้ง cpt2
TH105747B (th) รูปแบบผลึกของไนโตรเคทิคอล